Stay updated with breaking news from Ren Chi Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sovleplenib provided a statistically significant and clinically meaningful increase in durable response rate over placebo in adult patients with primary immune thrombocytopenia in China.
Hutchmed is planning to submit a New Drug Application (NDA) for treatment of primary immune thrombocytopenia (ITP) in China.
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — —...
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with...